Ikena Oncology (IKNA) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 16, 2026, to be held virtually for shareholder participation.

• Shareholders are encouraged to review proxy materials and vote on key proposals before June 15, 2026.

Voting matters and shareholder proposals

• Election of two Class II director nominees, David P. Bonita, M.D. and Joseph P. Slattery, to serve until the 2029 annual meeting.

• Ratification of PricewaterhouseCoopers LLP as independent auditor for the fiscal year ending December 31, 2026.

• Approval of amendment and restatement of the 2025 Equity Incentive Plan, increasing authorized shares by 850,000 and including convertible preferred stock and prefunded warrants in the annual share reserve calculation.

• Provision to transact any other business properly brought before the meeting or its adjournment.

Board of directors and corporate governance

• Board recommends voting in favor of all director nominees and proposals.